- Report
- August 2025
- 199 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 190 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 182 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 180 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 195 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- August 2025
- 188 Pages
Global
From €3174EUR$3,545USD£2,725GBP
€3526EUR$3,939USD£3,027GBP
- Report
- January 2024
- 200 Pages
Global
From €3715EUR$4,150USD£3,190GBP
- Report
- June 2025
- 193 Pages
Global
From €4029EUR$4,500USD£3,459GBP
- Report
- March 2025
- 180 Pages
Global
From €4029EUR$4,500USD£3,459GBP
- Report
- March 2025
- 182 Pages
Global
From €4029EUR$4,500USD£3,459GBP
- Report
- January 2025
- 180 Pages
Global
From €4029EUR$4,500USD£3,459GBP
- Report
- December 2024
- 85 Pages
Spain
From €3133EUR$3,500USD£2,690GBP
- Report
- August 2024
- 85 Pages
India
From €3133EUR$3,500USD£2,690GBP
- Report
- April 2024
- 180 Pages
Global
From €4029EUR$4,500USD£3,459GBP
- Report
- October 2023
- 138 Pages
North America
From €3581EUR$4,000USD£3,074GBP
- Report
- October 2023
- 122 Pages
North America
From €3581EUR$4,000USD£3,074GBP
- Report
- February 2024
- 170 Pages
Global
From €4029EUR$4,500USD£3,459GBP
- Report
- February 2024
- 190 Pages
Global
From €4029EUR$4,500USD£3,459GBP
- Report
- November 2023
- 77 Pages
France
From €3133EUR$3,500USD£2,690GBP
- Drug Pipelines
- July 2025
- 280 Pages
Global
From €2686EUR$3,000USD£2,306GBP

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more